PIM1 and diffuse large B-cell lymphoma: Correlation of nuclear PIM1 expression with disease stage, as well as a modest response to small-molecule inhibitors, suggests that PIM kinases are progression markers rather than primary therapeutic targets in DLBCL (Brault et al., 2012).